title: Effects of verapamil and propranolol on changes in extracellular K+, pH, and local activation during graded coronary flow in the pig.
abstract: The beta-adrenergic and calcium channel blocking agents are known to reduce heart rate and alter myocardial contractility. More recent evidence suggests that both agents affect the metabolic consequences of ischemia, independent of their effects on heart rate and contractility. We used a low-flow model of ischemia in swine with heart rate held constant by atrial pacing. Blood was shunted from the carotid artery to the left anterior descending coronary artery through a controlled-flow roller pump to assess the threshold flow for the rise in extracellular potassium ([K+]e) and fall in extracellular pH (pHe) associated with ischemia during control situations and after the administration of either propranolol or verapamil. We also measured the changes in activation delay and contractility associated with graded flow reductions in the presence and absence of these drugs. We found that when heart rate is held constant, 1) verapamil shifts the threshold flow for [K+]e and pHe to lower levels, but propranolol does not; 2) verapamil lessens activation delay, while propranolol aggravates the delay; and 3) verapamil reduces afterload and selectively depresses contractility in the reperfused ischemic zone. We conclude that the calcium channel blockers and the beta-adrenergic-blocking agents have different effects and possibly different modes of action and should not be considered interchangeable when evaluating therapeutic options for patients with ischemic heart disease.
authors.affiliation: Department of Medicine, University of North Carolina, Chapel Hill 27599.
authors.forename: I
authors.initials: I
authors.lastname: Watanabe
authors.forename: T A
authors.initials: TA
authors.lastname: Johnson
authors.forename: C L
authors.initials: CL
authors.lastname: Engle
authors.forename: C
authors.initials: C
authors.lastname: Graebner
authors.forename: M G
authors.initials: MG
authors.lastname: Jenkins
authors.forename: L S
authors.initials: LS
authors.lastname: Gettes
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy*; D006339:Heart Rate; D006863:Hydrogen-Ion Concentration; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism*; D011188:Potassium / Q000378:metabolism*; D011433:Propranolol / Q000494:pharmacology*; D013552:Swine; D014700:Verapamil / Q000494:pharmacology*
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D011433:Propranolol; D014700:Verapamil; D011188:Potassium